A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-1 mimetic (ABT-510) in patients with advanced cancer

被引：0
|
作者：
de Vos, FYFL
Hoekstra, R
Gietema, JA
Jager, PJ
Eskens, FALM
Carr, R
Guirguis, M
Humerickhouse, R
de Vries, EGE
Verweij, J
机构：
[1] Univ Groningen Hosp, Dept Med Oncol, Groningen, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Med Oncol, Rotterdam, Netherlands
[3] Univ Groningen Hosp, Dept Nucl Med, Groningen, Netherlands
[4] Abbott Labs, Clin Pharmacokinet Dept, Abbott Pk, IL 60064 USA
[5] Abbott Labs, Dept Oncol, Abbott Pk, IL 60064 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
248
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 50 条
  • [31] Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer
    Polee, MB
    Verweij, J
    Siersema, PD
    Tilanus, HW
    Splinter, TAW
    Stoter, G
    Van der Gaast, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (11) : 1495 - 1500
  • [32] A phase I study of weekly one hour escalating dose of paclitaxel infusion in conjunction with amifostine in patients with advanced cancer
    Akhtar, S
    Bradshaw, D
    Wright, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S294 - S294
  • [33] Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial
    Atmaca, A.
    Al-Batran, S-E
    Maurer, A.
    Neumann, A.
    Heinzel, T.
    Hentsch, B.
    Schwarz, S. E.
    Hovelmann, S.
    Goettlicher, M.
    Knuth, A.
    Jaeger, E.
    BRITISH JOURNAL OF CANCER, 2007, 97 (02) : 177 - 182
  • [34] Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
    A Atmaca
    S-E Al-Batran
    A Maurer
    A Neumann
    T Heinzel
    B Hentsch
    S E Schwarz
    S Hövelmann
    M Göttlicher
    A Knuth
    E Jäger
    British Journal of Cancer, 2007, 97 : 177 - 182
  • [35] Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells
    Isenberg, Jeff S.
    Yu, Christine
    Roberts, David D.
    BIOCHEMICAL PHARMACOLOGY, 2008, 75 (04) : 875 - 882
  • [36] Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
    Mross, Klaus
    Stefanic, Martin
    Gmehling, Daniela
    Frost, Annette
    Baas, Franziska
    Unger, Clemens
    Strecker, Ralph
    Henning, Juergen
    Gaschler-Markefski, Birgit
    Stopfer, Peter
    de Rossi, Lothar
    Kaiser, Rolf
    CLINICAL CANCER RESEARCH, 2010, 16 (01) : 311 - 319
  • [37] ESCALATING WEEKLY FIXED-DOSE OF NIMOTUZUMAB WITH CONCURRENT CHEMORADIOTHERAPY IN PATIENTS WITH ADVANCED OESOPHAGEAL CANCER - A PHASE 1 STUDY
    Zhao, K.
    Jiang, G.
    Hu, X.
    Wu, X.
    Fu, X.
    Fan, M.
    Yu, S.
    Chu, X.
    Liang, P.
    Zheng, J.
    EJC SUPPLEMENTS, 2011, 9 (01): : 19 - 20
  • [38] Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer
    Dudek, Arkadiusz Z.
    Larson, Timothy
    Keshtgarpour, Mani
    Kumar, Priya
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (05): : 481 - 486
  • [39] A phase I study of amifostine (AMI) and escalating doses of taxol in patients (PTS) with advanced cancer
    Schuchter, L
    DiPaola, R
    Greenberg, R
    Bird, S
    Mollman, J
    Recio, A
    List, A
    Taylor, C
    Alberts, D
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 958 - 958
  • [40] A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours
    Aung, Kyaw L.
    El-Khoueiry, Anthony B.
    Gelmon, Karen
    Tran, Ben
    Bajaj, Gaurav
    He, Bing
    Chen, Tian
    Zhu, Lili
    Poojary, Sharath
    Basak, Shashwati
    Qi, Zhenhao
    Spreafico, Anna
    Fischer, Bruce S.
    Desai, Jayesh
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1026 - 1036
12345